The Promise of Personalized Medicine

Perry Dimas
  • 5.0 (4)
  • MEDICINE
  • UPDATED BIWEEKLY

There is no personalized medicine without a diagnostic test to help in the process. The Promise of Personalized Medicine is a podcast that explores the process of creating more personalized medicine and the Medical Directors who ensure that the right care is being delivered to us all. Season 1 will focus on understanding best practices by using the Blueprint of Success format as a template for labs to use when trying to get their novel diagnostic test approved by health plans. This is The Promise of Personalized Medicine.

  1. 3D AGO

    Replay: Unraveling the Human Genome: From DNA to Personalized Health w/ Jill Davies

    Our DNA holds the keys to understanding our health and well-being. Our guest today is Jill Davies, CEO at Genome Medical. She emphasizes the crucial role of genetic counselors in deciphering complex genetic information for individuals, offering tailored guidance on healthcare decisions. Jill introduces the concept of genetic counseling assistants, streamlining the process and allowing genetic counselors to focus on the most critical aspects of patient care. The conversation also dives into: Sources of patient referralsBarriers to personalized medicine, including limited access to genetic counselors and concerns about payor coverage Advancements in testing methodologies Jill Davies is a leader in the field of genomic healthcare. With over 20 years of experience in the genomics field, Jill has broad expertise across clinical services, telehealth, strategic planning, business development and leadership. She has a special interest in the role of genomics in primary care and preventive medicine as well as the use of technology to enable access to genomic information and services. —---- Stay connected with our host, Perry Dimas, here on LinkedIn!  If you’re a Medical Director looking to advise laboratory innovators, please DM Perry on LinkedIn!

    21 min
  2. Access, Guidelines, and the Gap in Personalized Medicine w/ Dr. Federico Monzon

    FEB 9

    Access, Guidelines, and the Gap in Personalized Medicine w/ Dr. Federico Monzon

    What does personalized medicine really mean—and why does it remain so difficult to implement at scale? In this episode, Perry is joined by longtime colleague and molecular pathology expert Dr. Frederico Monzon for an in-depth conversation on the realities behind personalized medicine. Drawing from his experience across academia, clinical practice, and industry, Frederico reframes personalized medicine as not only identifying the right treatment—but also avoiding therapies that offer no benefit and may cause harm. In this episode, you’ll hear about: How personalized medicine has long existed in pathology, even before the term became a buzzword Why avoiding ineffective treatments is just as critical as finding the right one The ongoing challenge of access to diagnostic testing and actionable information Why many patients still aren’t tested—even when guidelines and coverage exist The role of clinical guidelines as guardrails, not rigid rules Tensions and opportunities between laboratories, insurers, and lab benefit managers How unmet clinical need drives meaningful innovation in diagnostics Why collaboration across industry, academia, and payers is essential What excites Frederico most about the future: multimodal medicine combining genomics, pathology, imaging, clinical data, and AI The conversation closes with a forward-looking discussion on how breaking down data silos—and using AI responsibly—could help healthcare teams deliver more precise, cost-effective care tailored to each individual patient. —------- Stay connected with our host, Perry Dimas, here on LinkedIn!    📧 Interested in joining our medical director advisory group? Email us at info@accessdx.com  🔗 Connect on LinkedIn: linkedin.com/company/accessdx

    26 min
  3. Replay: Test Innovations in Personalized Medicine: Overcoming Challenges and Embracing Change

    JAN 27

    Replay: Test Innovations in Personalized Medicine: Overcoming Challenges and Embracing Change

    Using genomics or other biomarkers to improve health care is the essence of Personalized Medicine according to today’s guest, Dr. Bruce Quinn. Moving forward with novel diagnostic testing could prove challenging for a variety of reasons, one of them being a disruption to the overall healthcare industry. If one test could replace multiple, costly tests, then the ROI for certain payors goes down.  Join us as we also discuss:  The other challenges facing new testsWhere test identifiers are headingThe indirect interest of insurance sales Dr. Quinn is the Principal at Bruce Quinn Associates LLC and is an expert in Medicare policy for innovative technology.  His initial career was as a full-time medical school faculty member.  Armed with an MBA in 2001, he shifted to a career in strategy consulting.  He served as a regional Medicare Part B medical director 2004-2008.   He has worked for a global consulting firm, Accenture, as well as for two DC-based health policy firms.    Since 2016, he has been an independent consulting primarily focused on genomics and digital technologies.  His services include product planning and reimbursement pathways for innovators, as well as due diligence investigations for investors.   His website on health policy and new technology, “Discoveries in Health Policy,” has had over a million views, holds 2000 articles, and has hundreds of subscribers from industry, academia, and government.  Dr. Quinn is based in Los Angeles. —---- Stay connected with our host, Perry Dimas, here on LinkedIn!

    21 min
  4. Rethinking Precision Medicine: From Mutations to Molecular Pathways

    JAN 13

    Rethinking Precision Medicine: From Mutations to Molecular Pathways

    In this episode of The Promise of Personalized Medicine, Perry sits down with Aditya Pai, a genetic counselor by training and a leader at Genialis, where he works at the intersection of biology-driven analytics, AI, and oncology drug development. Aditya brings a practitioner’s and innovator’s perspective to what personalized medicine truly means today—moving beyond one-size-fits-all care and even beyond single-gene mutations, toward a more holistic understanding of disease biology. Together, they explore how RNA-based insights, pathway-level analysis, and machine learning are reshaping how cancers are understood, treated, and studied across the drug development lifecycle. Aditya shares insights about: Why personalized medicine is not new—but how advances in AI, transcriptomics, and systems biology are making it more actionable than ever How biology-driven, pathway-level approaches outperform single-mutation thinking in complex diseases like cancer The role of AI and machine learning in building “foundation models” for cancer that help explain response, resistance, and relapse Using therapeutic intelligence to improve drug discovery, clinical trial design, patient stratification, and combination therapy decisions How diagnostics are increasingly guiding therapeutics, and why elevating the value of diagnostic insights is critical to accelerating adoption The continued importance of clinical guidelines—and how they can coexist with truly individualized care Real-world examples where understanding underlying biology unlocked better outcomes, even when mutations alone fell short This episode offers a thoughtful, forward-looking look at how personalized medicine is evolving—from clinical care to population-level insights—and what it will take to translate cutting-edge science into meaningful, ethical, and accessible outcomes for patients. —------- Stay connected with our host, Perry Dimas, here on LinkedIn! 📧 Interested in joining our medical director advisory group? Email us at info@accessdx.com 🔗 Connect on LinkedIn: linkedin.com/company/accessdx

    24 min

  5. 11/12/2025

    DX Con 2025 Recap!

    In this episode of The Promise of Personalized Medicine, host Perry Dimas recaps highlights from the recent Diagnostics Conference in Napa—a gathering that brought together leaders and innovators shaping the future of precision medicine. Perry shares key takeaways from the event, including thought-provoking discussions on data aggregation for faster industry adoption, insights from MetaCensus on collaborative progress, and a critical legal update from Debbie Parish of Parish Law. He also reflects on Bobbi Buell’s presentation, which explored what the diagnostics industry can learn from pharma’s success in driving education, adoption, and payer alignment. The episode also spotlights an attendee favorite: the Medical Director Workshop, where participants had the rare opportunity to meet with multiple advisors in small groups to refine their company messaging and payer strategies. If you’re interested in attending DX Con 2026, please visit our website to register now!  —------- Stay connected with our host, Perry Dimas, here on LinkedIn! 📧 Interested in joining our medical director advisory group? Email us at info@accessdx.com 🔗 Connect on LinkedIn: linkedin.com/company/accessdx

    5 min

  6. 09/16/2025

    What Counts as Proof? Personalized Medicine and Coverage Pathways w/ Eugean Jiwanmall

    In this episode of The Promise of Personalized Medicine, Perry sits down Eugean Jimanwall, Senior Research Analyst for Medical Policy & Technology Evaluation at Independence Blue Cross’ Medical & Claim Payment Policy Department within Facilitated Health Networks and Medical Affairs. He is a seasoned expert with more than 15 years of experience in medical policy and health technology assessment. Together, they unpack the evolving world of personalized and precision medicine—what it really means, why the concept isn’t new, and how modern tools like next-generation sequencing and biomarkers are advancing accuracy in care. Eugene shares insights about: Reviewing evidence for medical policy, highlighting both the opportunities and common challenges companies face when validating new tests The importance of clinical utility data to the role of biomarkers in shaping treatment decisionsThe necessity of aligning evidence generation (validity, utility, etc.) with what payors, policy bodies, or HTA organizations requireNeed for clinically meaningful improvements, not just statistical significance. What matters in practice (improved management, symptom relief, survival, quality of life).While personalized medicine is about the individual, policy / reimbursement / HTA often think in terms of subpopulations (e.g. groups with a biomarker) or larger cohorts. This episode offers a candid, expert perspective on what it takes to move from theory to meaningful outcomes. —------- Stay connected with our host, Perry Dimas, here on LinkedIn! 📧 Interested in joining our medical director advisory group? Email us at info@accessdx.com 🔗 Connect on LinkedIn: linkedin.com/company/accessdx

    36 min
  7. Precision Care Beyond the Pill: How Personalized Medicine is Changing Healthcare

    08/26/2025

    Precision Care Beyond the Pill: How Personalized Medicine is Changing Healthcare

    In this episode of The Promise of Personalized Medicine, Perry sits down with Dr. Neetu Sharma to explore the evolving world of precision medicine and how it’s transforming patient care. From the role of genetics and biomarkers in tailoring treatment to the importance of lifestyle, environment, and early intervention, Dr. Sharma offers a holistic view of what personalized medicine truly means. They discuss real-world applications, including chronic kidney disease, and how genetic testing can guide treatment decisions, improve outcomes, and even reduce healthcare costs. Perry and Dr. Sharma also tackle the challenges facing the field—from data privacy and payer adoption to the tension between clinical guidelines and individualized care—and the critical need for patients to take ownership of their health. Whether you’re a healthcare professional, patient, or simply curious about the future of medicine, this conversation highlights how precision care goes beyond symptom management, empowering both doctors and patients to act upstream and prevent chronic disease before it starts. —------- Stay connected with our host, Perry Dimas, here on LinkedIn! 📧 Interested in joining our medical director advisory group? Email us at info@accessdx.com 🔗 Connect on LinkedIn: linkedin.com/company/accessdx

    27 min

  8. 08/12/2025

    Making Personalized Medicine Boring: Why That’s the Goal w/ Dr. Ryan Nelson

    In this episode of The Promise of Personalized Medicine, Perry sits down with Dr. Ryan Nelson, to explore the evolving and sometimes misunderstood world of personalized medicine.  With years of hands-on experience, Dr. Nelson offers a refreshingly nuanced definition—one that goes beyond genetics to include biomarkers, digital tools, and system-wide collaboration for predictive, preventative, and precisely tailored care. We dive deep into: the challenges and slow adoption of pharmacogenetics in the U.S.the ethical and regulatory friction surrounding genetic testingwhy "genetic exceptionalism" may actually hinder progressthe FDA’s shifting role to real-world cost savings dataRyan also shares a behind-the-scenes look at MetaCensus, a new distributed platform designed to foster consensus among stakeholders through open-access, federated data—creating space for payers, providers, pharma, and regulators to weigh evidence transparently. —------- Stay connected with our host, Perry Dimas, here on LinkedIn! 📧 Interested in joining our medical director advisory group? Email us at info@accessdx.com 🔗 Connect on LinkedIn: linkedin.com/company/accessdx

    29 min
See All (35)

Ratings & Reviews

5
out of 5
4 Ratings

About

There is no personalized medicine without a diagnostic test to help in the process. The Promise of Personalized Medicine is a podcast that explores the process of creating more personalized medicine and the Medical Directors who ensure that the right care is being delivered to us all. Season 1 will focus on understanding best practices by using the Blueprint of Success format as a template for labs to use when trying to get their novel diagnostic test approved by health plans. This is The Promise of Personalized Medicine.

Information